Purchase Order HT001422P0241
Award Date 9/29/22
Potential Completion Date 10/26/22
Potential Value $139K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20889, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Health Agency (DHA) has awarded a $139,428 firm fixed price purchase order to Biotheranostics Inc., a self-certified small disadvantaged business, to provide Breast Cancer Index testing services. This award, with a completion date of September 25, 2024, is not set aside and supports the DHA's efforts to enhance cancer care for veterans and service members through advanced molecular diagnostics that guide treatment planning. Biotheranostics, a division of Hologic, Inc., has...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Biotheranostics Inc., a self-certified small disadvantaged business, to provide Breast Cancer Index testing services for the Walter Reed National Military Medical Center. The $96,825 contract does not have a set-aside designation. Biotheranostics specializes in providing genomic diagnostic testing to support precision oncology and has been awarded multiple federal contracts by the Department of Veterans...
- The Defense Health Agency awarded a $139,428 firm fixed price purchase order to Biotheranostics Inc., a small disadvantaged business specializing in advanced molecular diagnostics and genomic testing services. The contract, which commenced on September 30, 2025 with an ultimate completion date of October 30, 2025, covers Breast Cancer Index (BCI) testing services to be performed at the Bethesda, Maryland location. This award represents a continuation of DHA's precision oncology efforts,...
- This is a $256,599.00 firm fixed price purchase order awarded by the Department of Veterans Affairs' Veterans Integrated Service Network 17 to Biotheranostics Inc., a self-certified small disadvantaged business and division of Hologic, Inc. The contract is for the provision of the Breast Cancer Index (BCI) diagnostic test. The BCI test leverages genomic analysis to aid in cancer screening, diagnosis, and treatment planning. This award is not set aside and is one of several prime federal...
- Biotheranostics Inc., a small disadvantaged business and division of Hologic Inc., was awarded a $47.4K purchase order by Veterans Integrated Service Network 6 (VISN 6) for cancer identification testing services. The contract, issued on October 7, 2021, with an ultimate completion date of October 6, 2026, utilizes firm fixed-price pricing with no set-aside designation. Performance will occur in San Diego, California, where Biotheranostics maintains its headquarters and specializes in advanced...
- This federal contract award to Genomic Health, Inc. is for the provision of breast cancer testing services to the Defense Health Agency (DHA), a defense agency within the U.S. Department of Defense. The $125,000.00 Firm Fixed Price Blanket Purchase Agreement (BPA) contract does not utilize any set-aside designations and was awarded on September 21, 2016, with a completion date of September 20, 2017. Genomic Health, a subsidiary of Exact Sciences Corporation, specializes in genomic-based cancer...
- This federal contract award to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, is for the provision of the company's Oncotype DX portfolio of cancer diagnostic assays. The contract, valued at $200,327.28, was awarded by the Veterans Integrated Service Network 6 (VISN 6) of the U.S. Department of Veterans Affairs (VA). It is a firm-fixed-price purchase order with a period of performance through September 30, 2025. The contract does not utilize a set-aside designation, as Genomic...
- This is a firm fixed-price BPA call order awarded by the Department of Veterans Affairs (VA) to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation. The contract, valued at $3,453.96, is for the provision of express cancer testing services, specifically Oncotype DX assays, to support the VA's healthcare programs. Genomic Health, as a provider of genomic-based cancer diagnostic tests, has received numerous prime and subcontractor awards from various federal agencies, including the...
- The Defense Health Agency awarded Genomic Health, Inc. a $145,066.32 firm fixed-price BPA call for Oncotype IQ genomic testing services, with an ultimate completion date of September 7, 2026. Genomic Health, a subsidiary of Exact Sciences Corporation, specializes in advanced genetic testing services focused on oncology diagnostics, particularly the Oncotype DX portfolio of gene expression assays. These tests support cancer screening, treatment selection, and disease monitoring across breast,...
- The Defense Health Agency has awarded a delivery order valued at $777,141 to Exact Sciences Corporation for Oncotype DX Breast CPT 81519 testing services, with performance scheduled through February 11, 2030. This contract was awarded under the GSA Schedule Medical Laboratory Testing and Analysis Services (FSS-621-II) without a set-aside designation, reflecting Exact Sciences' competitive positioning as a specialized provider of genomic diagnostic testing. The work will be performed at Fort...